All In Biotech

Drug Trial Radar · NCT05831176

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

22

Actual

Start

May 3, 2023

Primary completion

Feb 23, 2026

Study completion Nov 25, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Apr 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the effect of dupilumab on relieving EoG (with or without EoD) symptoms and reducing inflammation in the stomach and, if applicable, small intestine in adults and adolescents aged 12 years and older after at least 24 weeks (about 6 months) and up to 52 weeks (1 year) of treatment. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Eosinophilic Gastritis (EoG)
  • Eosinophilic Duodenitis (EoD)
  • Eosinophilic Gastrointestinal Disease (EGID)
  • Eosinophilic Gastroenteritis

Interventions

  • DupilumabDrug

    Administered as described in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in peak gastric eosinophil count eosinophils/high power field (eos/hpf)Time frame: Baseline up to 24 Weeks

Locations

53 sites in 4 countries. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Om Research LLC

    Apple Valley, California

  • Scripps Clinic

    La Jolla, California

  • Om Research LLC

    Lancaster, California

  • University of California - Los Angeles (UCLA)

    Los Angeles, California

  • University of Southern California Keck School of Medicine

    Los Angeles, California

  • GastroIntestinal BioSciences

    Los Angeles, California

  • United Medical Doctors

    Murrieta, California

  • Ucsf Medical Center (Benioff Childrens Hospital)

    San Francisco, California

  • University of Colorado Anschutz Health Science Building (AHSB) CU Research Pharmacy

    Aurora, Colorado

  • Connecticut Clinical Research Institute

    Bristol, Connecticut

  • UConn Health

    Farmington, Connecticut

  • Encore Borland-Groover Clinical Research

    Jacksonville, Florida

  • Northwestern University

    Chicago, Illinois

  • University Of Kansas

    Kansas City, Kansas

  • Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • MNGI Digestive Health P.A.

    Plymouth, Minnesota

  • Mayo Clinic Hospital Rochester

    Rochester, Minnesota

  • Advanced Research Institute

    Reno, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Northwell Health

    Great Neck, New York

  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Charlotte Gastroenterology & Hepatology, PLLC

    Charlotte, North Carolina

  • Duke University

    Durham, North Carolina

  • ESI Medical Research, PLLC

    Kinston, North Carolina

  • University of Cincinnati Medical Center-Children's Hospital Medical Center

    Cincinnati, Ohio

  • Ohio State University Medical Center

    Columbus, Ohio

  • Allergy, Asthma and Clinical Research Center

    Oklahoma City, Oklahoma

  • The Oregon Clinic - Gastroenterology East

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • TDDC dba GI Alliance Research

    Mansfield, Texas

  • University of Utah

    Salt Lake City, Utah

  • Seattle Children's Home Health Company

    Seattle, Washington

  • Froedtert Hospital

    Milwaukee, Wisconsin

  • Stollery Children's Hospital - University of Alberta

    Edmonton, Alberta, Canada

  • U.O. Di Ematologia-Azienda Policlinico Consorziale, Ospedaliero-Universitaria, Ospedale

    Bari, Italy

  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - Centro Clinico Nemo (Neuro Muscular Omnicentre)

    Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.